Publicacions en què col·labora amb Manuel Ramos Casals (25)

2022

  1. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Annals of the rheumatic diseases, Vol. 81, Núm. 3, pp. 370-378

  2. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

    Arthritis Care and Research, Vol. 74, Núm. 4, pp. 638-647

  3. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications

    Arthritis Care and Research, Vol. 73, Núm. 12, pp. 1789-1795

2020

  1. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

    Arthritis and Rheumatology, Vol. 72, Núm. 10, pp. 1734-1740

2018

  1. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort

    Rheumatology (United Kingdom), Vol. 57, Núm. 4, pp. 677-687

2017

  1. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

    Lupus, Vol. 26, Núm. 10, pp. 1051-1059

2016

  1. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach

    Arthritis and Rheumatology, Vol. 68, Núm. 8, pp. 1932-1944

  2. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  3. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 9, pp. 1706-1713

  2. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 8, pp. 1530-1536

  3. Mood disorders in systemic lupus erythematosus: Results from an international inception cohort study

    Arthritis and Rheumatology, Vol. 67, Núm. 7, pp. 1837-1847

  4. The frequency and outcome of lupus nephritis: Results from an international inception cohort study

    Rheumatology (United Kingdom), Vol. 55, Núm. 2, pp. 252-262

2014

  1. Erratum: Incorrect values for intractable and cluster headaches at enrollment shown in figure 1 and incorrect prevalence of headache at ten years in text of the article by hanly et al (Arthritis and Rheumatology (2013))

    Arthritis and Rheumatology

2013

  1. Belimumab en el lupus eritematoso sistémico: una guía para su uso en la práctica diaria

    Revista Clinica Espanola

  2. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 8, pp. 1308-1314

  3. Headache in systemic lupus erythematosus: Results from a prospective, international inception cohort study

    Arthritis and Rheumatism, Vol. 65, Núm. 11, pp. 2887-2897

  4. Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI

    Revista Clinica Espanola, Vol. 213, Núm. 1, pp. 42-58

2012

  1. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

    Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364